MMWR: Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, Ju

[tetano]

Amanda B. Payne, PhD[SUP]1[/SUP]; Logan C. Ray, MPH[SUP]1[/SUP]; Matthew M. Cole, MPH[SUP]1[/SUP]; Michelle Canning, MPH[SUP]1[/SUP]; Kennedy Houck, MPH[SUP]1[/SUP]; Hazel J. Shah, MPH[SUP]1[/SUP]; Jennifer L. Farrar, MPH[SUP]1[/SUP]; Nathaniel M. Lewis, PhD[SUP]1[/SUP]; Amy Fothergill, PhD[SUP]1[/SUP][SUP],2[/SUP]; Elizabeth B. White, PhD[SUP]1[/SUP][SUP],2[/SUP]; Leora R. Feldstein, PhD[SUP]1[/SUP]; Lauren E. Roper, MPH[SUP]1[/SUP]; Florence Lee, MPH[SUP]1[/SUP]; Jennifer L. Kriss, PhD[SUP]1[/SUP]; Emily Sims, MPH[SUP]1[/SUP]; Ian H. Spicknall, PhD[SUP]1[/SUP]; Yoshinori Nakazawa, PhD[SUP]1[/SUP]; Adi V. Gundlapalli, MD, PhD[SUP]1[/SUP]; Tom Shimabukuro, MD[SUP]1[/SUP]; Adam L. Cohen, MD[SUP]1[/SUP]; Margaret A. Honein, PhD[SUP]1[/SUP]; Jonathan Mermin, MD[SUP]1[/SUP]; Daniel C. Payne, PhD


Among JYNNEOS vaccine-eligible men aged 18–49 years in 43 U.S. jurisdictions, mpox incidence among unvaccinated persons was 9.6 times as high as that among persons who had received 2 vaccine doses and 7.4 times as high as that among persons who had received only the first dose. Preliminary evidence indicates no difference in protection between subcutaneous and intradermal administration routes.


https://www.cdc.gov/mmwr/volumes/71...X4NZBQoGU_GhP100umkdv72nBnnY_lpdl94QHZt_5Vvnw